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Background: Recent vasodilating drugs have improved prognosis of Pulmonary arterial hypertension (PAH). Some
reports describe the merits of combination therapies for PAH, and this study evaluated the efficacy and safety of
phosphodiesterase type 5 inhibitors (PDE5i) combination therapy, using sildenafil and tadalafil, for multi-drug-resistant
PAH.
Methods: We retrospectively analyzed 7 consecutive refractory patients with PAH administered either sildenafil 60 mg
or tadalafil 40 mg as well as both ERA and prostanoid as combination therapies. All were started on the dual PDE5i
(sildenafil and tadalafil at maximum dose).
Results: Treatment was generally well tolerated without severe adverse events. On completion of the study, the seven
patients received right heart catheterization and the 6-minute walk test (6WMT) 9.6 ± 1.4 months after initiation of the
dual PDE5i therapy, showing significant improvements in hemodynamic parameters and exercise tolerance. Mean
pulmonary arterial pressure and pulmonary vascular resistance decreased from 47.9 ± 9.7 to 41.7 ± 9.2 mmHg (P = 0.004)
and 9.3 ± 2.7 to 6.7 ± 2.9 mmHg (P = 0.018), respectively. Cardiac index and 6MWT also increased from 2.8 ± 0.9 to
3.1 ± 0.8 L/min/m2 (P = 0.026) and 353 ± 60 to 382 ± 62 m (P = 0.014), respectively.
Conclusion: The findings support dual PDE5i therapy as a new treatment option for refractory PAH.
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Pulmonary arterial hypertension (PAH) is a progressive
and fatal disease characterized by degeneration of the
pulmonary arteries and subsequent increased pulmonary
vascular resistance (PVR). These adverse effects lead to
an increase in pulmonary arterial pressure (PAP) and
high ventricular pressure overload, resulting in irreversible
right heart failure.
The pathogenesis of PAH is partially characterized by
the reduced expression of nitric oxide synthase in the
pulmonary arterial vascular endothelial cells [1], which
leads to impaired release of nitric oxide in pulmonary
arteries [2]. From these findings, phosphodiesterase type 5* Correspondence: u1@ta-mu.net
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unless otherwise stated.inhibitors (PDE5i) were proposed as potentially potent
drugs against PAH that would act by increasing the cyclic
guanosine monophosphate (cGMP) levels to induce the
vasodilating [3] effects of endogenous nitric oxide.
Controlled trials of sildenafil, tadalafil and valdenafil for
the treatment of patients with PAH showed improvements
in exercise capacity, hemodynamic parameters and clinical
outcome [4-7]. However, the currently approved dose of
sildenafil is derived from that used to improve exercise
capacity in the clinical study, and current reports suggest
that the 6-minute walk test (6MWT) is insufficient as a
surrogate endpoint in clinical trials for PAH [8,9], instead
recommending improvements in PVR and time to clinical
worsening as endpoints. Indeed, the SUPER-1 [5] and
SUPER-2 [10] trials showed dosage-dependent improve-
ments in hemodynamics (both in PAP and PVR) with a
dose fourfold higher than the currently approved clinicalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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could play a role in salvage therapy for multi-drug refrac-
tory PAH, realized by taking the PDE5 inhibitors, sildenafil
and tadalafil, at the maximum approved dose.
This report describes the results of a retrospective
study of the effects of dual PDE5 inhibitor therapy
with sildenafil and tadalafil as a salvage therapy for
multi-drug-resistant PAH.
Methods
This study is a retrospective study. This study followed
the ethical standards of the responsible committee on
human experimentation (KEIO UNIVERSITY SCHOOL
OF MEDICINE AN ETHICAL COMMITTEE, Tokyo,
Japan; the approval code is 20100008) and the Helsinki
Declaration of 1975, as revised in 2000. And written
informed consent was obtained from all patients in the
study. A total of 142 patients with pulmonary hypertension
were treated at Keio University Hospital (Tokyo, Japan)
from April 2009 to May 2013, and 104 of these were
diagnosed with PAH, classified according to the Dana
Point classification of PH [11]. Of the PAH patients,
26.9% (n = 28) received triple combination therapy
with prostanoids, ERA, and PDE5i. Among them,
seven consecutive patients with refractory PAH were
treated with both PDE5i used in combination as a
salvage therapy. The refractory PAH was defined as
the patients suffering from the symptom of NYHA III
or IV in spite of taking three kinds of PAH specific drugs.
These seven patients had previously been treated with a
single PDE5 inhibitor (PDE5i) at the maximum dose,
either sildenafil (60 mg per day) or tadalafil (40 mg per
day), as well as both endothelin receptor antagonist (ERA)
and prostanoid as combination therapies. However, all
patients retained a diagnosis of refractory PAH despite
the three kinds of vasodilation therapies over at least 6
months. Accordingly, they were started on a salvage
therapy of dual-administered PDE5i, sildenafil and tadalafil,
used at the maximum dose, between August 2011 and
December 2012. For our control patients group, we
selected 10 patients with PAH (idiopathic or connective
tissue disease associated) from the same cohort. The
control patients were also performed continuous triple
combination therapies and hemodynamic measurements
but free from dual PDE5i therapy. And they were not
performed any additional PH specific therapies during the
observation period.
Right heart catheterization (RHC) and 6MWT were
performed before and within several months after the
initiation of combination therapy. Patient files and the
clinical database were reviewed and data were collected
on treatments for pulmonary hypertension (epoprostenol,
prostanoids, ERA, PDE5i), adverse events, the New York
Heart Association (NYHA) functional classification (FC),6MWT, and hemodynamic data (mean PAP, PVR and
cardiac index (CI)) assessed by RHC. Changes in
hemodynamic data and 6MWT, before and after the
initiation of combination therapy, were evaluated as
endpoints. The NYHA FC of patients was allocated by the
treating physician at the time of clinical assessment,
according to the WHO Functional Classification of PAH
(whereby an FC of 1–4 is derived from patient symptoms
in relation to exercise capacity).
Statistical methods
Statistical analyses were performed using SPSS version
21. Mean PAP, CI, and 6MWT exhibited normal distribu-
tions, so a paired t-test was performed to analyze these
data. Only PVR data after the initiation of combination
therapy did not exhibit a normal distribution, so the
Wilcoxon signed-rank test was performed to analyze
changes in PVR. A two-sided P-value of 0.05 was considered
to be statistically significant.
Results
A total of 142 patients with pulmonary hypertension
were treated at our hospital from April 2009 to May
2013, and 104 of these were diagnosed with PAH. Of the
PAH patients, 26.9% (n = 28) received triple combination
therapy with prostanoids, ERA, and PDE5i. Among
them, seven patients with refractory PAH were treated
with both PDE5i used in combination as a salvage therapy.
Table 1 details patient characteristics, including diagnosis,
vasodilator treatment and treatment duration. The patients
with refractory PAH were classified as idiopathic PAH
(n = 3), heritable PAH (n = 1) or congenital systemic-to-
pulmonary shunts (n = 1), associated with connective
tissue disease (CTD-PAH; n = 1) or associated with
neurofibromatosis (NF1-PH; n = 1). The mean patient
age (± SD) was 39.9 ± 12.3 years (range 23–55 years),
and all subjects were female. The mean disease duration
(± SD) was 6.6 ± 2.6 years (range 3–10 years). One patient
showed NYHA FC VI and all the others showed FC III.
Six patients had taken sildenafil (60 mg per day), and one
had received tadalafil (40 mg per day) previously. One
patient had also received ambrisentan and the other six
were given bosentan as ERA, while three patients received
intravenous epoprostenol infusion and four had beraprost
as prostanoids. The dosage of ERA and prostanoids were
not changed either 3 months before the initiations of dual
PDE5i therapy or during the study.
Complications of therapy are shown in Table 2. No severe
adverse effects were observed with the combination therapy
of PDE5i including hypotension, but some patients suffered
from headache and diarrhea during the observation period.
There was no dropout due to death, lung transplantation,
heart failure or drug escalation, and every patient could
continue the therapy during the follow up period.















mPAP (mmHg) PVR (WU) CI (L/min/m2)
41 F CTD-PAH 5 III 37 7.05 3.09 457 Sil, Be, Am 6
48 F ASD-PAH 8 III 53 10.43 1.65 336 Sil, Be, Bos 12
38 F NF1-PAH 9 III 55 13.8 2.29 330 Sil, Be, Bos 13
58 F HPAH 10 IV 38 7.36 2.88 320 Sil, Epo, Bos 10
23 F IPAH 3 III 40 7.3 2.94 390 Tad, Epo, Bos 14
26 F IPAH 7 III 62 7.49 4.39 370 Sil, Epo, Bos 3
45 F IPAH 4 III 50 12 2.22 267 Sil, Be, Bos 9
CTD: connective tissue disease, ASD: atrial septal defect, NF1: neurofibromatosis 1, HPAH: heritable pulmonary arterial hypertension, IPAH: idiopathic pulmonary
arterial hypertension, mPAP: mean pulmonary arterial pressure, PVR: pulmonary vascular resistance, WU: Wood’s units, CI: cardiac index, 6MWD: six-minute walk
distance, Sil: sildenafil, Tad: tadalafil, Be: beraprost, Epo: epoprostenol, Bos: bosentan, Am: ambrisentan.
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months after the initiation of the PDE5i combination
therapy. The effect of combination therapy on mPAP, PVR,
CI, and 6MWT are shown in Figure 1a to d, respectively,
with all parameters showing significant improvement.
Mean PAP improved from 47.9 ± 9.7 mmHg to 41.7 ± 9.2
mmHg, PVR from 9.3 ± 2.7 Wood’s Units to 6.7 ± 2.9
Wood’s Units, CI from 2.8 ± 0.9 L/min/m2 to 3.1 ± 0.8
L/min/m2 and 6MWT from 353 ± 60 m to 382 ± 62 m.
The effect of combination therapy on NYHA FC was also
shown in Figure 1e.
Finally we compared the patients with control patients
who had similar characteristics but free from dual PDE5i
therapy. Table 3 shows the details of patient characteris-
tics, including treatment duration periods, baseline
hemodynamic parameters and the changes after the
contibuation of triple combination therapies. While the
control patients also provided triple combination therapies
with PDE5i, ERA and prostanoids, they acquired no
hemodynamic improvements with the continuation of triple
combination therapies. On the other hand, dual PDE5i
therapy showed significant hemodynamic improvements
compared with the control group.
Discussions
In this uncontrolled, retrospective observational study of
patients with PAH treated with both sildenafil and tadalafil,
we achieved significant improvement in hemodynamic
parameters as well as exercise tolerance despite the
conditions of PAH being severe and refractory for
combination therapy. In the previous SUPER [5] and




Hot Flash 4improved 6MWD and FC in the short term. Nevertheless,
half of the enrolled patients in PHIRST study group were
initially treated with bosentan.
When to change treatment, or add an agent, in patients
with PAH remain unanswered questions. However, the
progressive and degenerative nature of PAH, as well as
recent reports of improved therapeutic agents [12-15],
provide encouragement to consider more aggressive
approved therapy in patients showing no improvement.
Combination therapies, with potentially additive or syner-
gistic effects, are being explored. Indeed, targeted therapies
significantly improved 6MWD and relative risk of death in
a meta-analysis of studies in patients with PAH [16]. This is
important considering that patients with poor exercise
tolerance at baseline and whose 6MWD failed to improve
after the initial treatments showed reduced long-term
survival [10], suggesting a particularly poor prognosis
without appropriate additional early therapy.
In this study, we found that additional treatment with
a second PDE5i achieved significant improvement of
PAH, suggesting that PDE5i dual combination therapy
could work well as a salvage therapy in patients with
severe and refractory PAH. One of the possible mecha-
nisms underlying the observed improvement is that PDE5i
are high-potency vasodilators, indicating that the approved
dose of sildanfil (60 mg/day) or tadalafil (40 mg/day) does
not fully inhibit PDE5 in the pulmonary vasculatures
and the dual PDE5i are needed to sufficiently increase
cGMP levels to have the desired therapeutic effect. In
fact, the SUPER study [5] showed that sildenafil achieved
dose-dependent improvements in hemodynamic parame-
ters within a short time in a dose range of 60 mg to 240
mg/day. The PHIRST study [7] also showed statistically
significant improvement in CI only in the tadalafil 40 mg
group, but not for patients receiving 2.5, 10 or 20 mg/day.
There are no data about the effectiveness of tadalafil
used at more than 40 mg in a day. Such data strongly
suggested that the effectiveness of PDE5 inhibition is
dose dependent, and importantly, that PDE5i use would
Figure 1 Hemodynamic and symptomatic changes before and after the dual PDE5i therapy. a. Effect of PDE5i dual therapy on mPAP. The red
line indicates mean change of mPAP (± SD) from 47.9 ± 9.7 mmHg to 41.7 ± 9.2 mmHg. b. Effect of PDE5i dual therapy on PVR. The red line
indicates mean change of PVR (± SD) from 9.3 ± 2.7 Wood’s Units to 6.7 ± 2.9 Wood’s Units. c. Effect of PDE5i dual therapy on CI. The red line
indicates mean change of CI (± SD) from 2.8 ± 0.9 L/min/m2 to 3.1 ± 0.8 L/min/m2. d. Effect of PDE5i dual therapy on 6MWTD. The red line
indicates mean change of 6MWD (± SD) from 353 ± 60 m to 382 ± 62 m. e. Effect of PDE5i dual therapy on NYHA functional class. mPAP: mean
pulmonary artery pressure, PVR: pulmonary vascular resistance, WU: Wood’s units, CI: cardiac index, 6MWD: six minutes walk distance.
Table 3 Comparison between dual PDE5i therapy group
and historical control
Dual PDE5i




Age (years) 39.9 ± 12.3 33.0 ± 12.1 0.271
Number of Female 7 (100%) 10 (100%) N/A
Follow-up period
(months)
9.6 ± 4.0 10.7 ± 1.8 0.438
mPAP (mmHg) 47.9 ± 9.7 46.2 ± 7.8 0.700
ΔmPAP at follow-up
(mmHg)
−6.1 ± 3.6 0.7 ± 3.3 0.001
PVR (WU) 9.3 ± 2.7 10.9 ± 5.0 0.458
ΔPVR at follow-up (WU) −2.6 ± 2.1 1.5 ± 2.2 0.001
CI (L/min/m2) 2.8 ± 0.9 2.8 ± 1.0 0.983
ΔCI at follow-up
(L/min/m2)
0.3 ± 0.3 −0.4 ± 0.6 0.007
mPAP: mean pulmonary artery pressure, PVR: pulmonary vascular resistance,
WU: Wood’s units, CI: cardiac index.
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approved.
Another mechanism of the improvement of the improve-
ment is the pharmacokinetic interactions between bosentan
and sildenafil or tadalafil. Sildenafil is predominantly metab-
olized by cytochrome P450 (CYP) 3A4 and CYP2C9, while
tadalafil is mainly metabolized by CYP 3A4. As bosentan in-
duces both CYP3A4 and CYP2C9 [17], a pharmacokinetic
interaction is possible between these agents. With the com-
bination of bosentan, the maximum plasma concentration
of sildenafil decreased by 55.4% [18] and the maximum
plasma concentration of tadalafil also decreased by 26.6%
[19], while combinations with bosentan and PDE5i were
generally well tolerated. In this study, 86% of patients (n = 6)
had already received bosentan before the initiation of PDE5i
combination therapy, and 5 patients out of 6 received
sildenafil and bosentan combination therapy. This fact sug-
gested that compared with the PDE5i used alone, the effect
of PDE5i used in combination was diminished by bosentan.
In addition, changing from the single to dual PDE5i use
recovered the degradation effect of PDE5 inhibition.
Kimura et al. BMC Pulmonary Medicine  (2015) 15:62 Page 5 of 5Study limitations
The limitation of our study is this was a single center
and retrospective study. Additional investigations such
as a multi-centre placebo-controlled study should be
performed to confirm the usefulness of PDE5i dual
therapy. In addition, data from the STARTS-2 study
[20] on sildenafil treatment for pediatric patients with
PAH, showed a favorable prognostic improvement in
patients given a medium dose for weight compared
with the maximum dose group. Thus, the appropriate
level of PDE5 inhibition needed to achieve the best prog-
nosis remains unknown and could differ among patients
groups. Further investigation is needed to determine the
optimal dosing of PDE5i.
Conclusion
In conclusion, this study demonstrates the safety and
efficacy of combination therapy with sildenafil and
tadalafil for the treatment of patients with severe
PAH. The favorable efficacy-to-safety profile of the dual
PDE5 inhibitors therapy provides a clinically meaningful
new treatment option in addition to the currently approved
treatment strategies.
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